Guggenheim raised the firm’s price target on Castle Biosciences (CSTL) to $43 from $30 and keeps a Buy rating on the shares. The firm adjusted its models and forecasts for its covered Diagnostics and Life Sciences Tools companies to reflect recent updates from the companies after meetings with management teams.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- Castle Biosciences price target raised to $50 from $37 at Canaccord
- Castle Biosciences reports inducement grants under Nasdaq listing rule
- Castle Biosciences announces new data on DecisionDx-UM, PRAME
- Castle Biosciences price target raised to $50 from $38 at BTIG
- Castle Biosciences announces publication of new SRMA on TissueCypher